第一部分 奋斗历程 1
中国遗传药理学的开拓者——记中国工程院院士周宏灏 3
第二部分 学术贡献 33
一、周宏灏院士的学术成就与学术思想 35
二、周宏灏院士的主要学术论文 42
Single-Dose Pharmacokinetics of Ceftriaxone in Healthy Chinese Adults 42
Racial Differences in Drug Response Altered Sensitivity to and Clearance of Propranolol in Men of Chinese Descent as Compared with American Whites 48
Interindividual Differences in β-receptor Density Contribute to Variability in Response toβ-adrenoceptor Antagonists 56
Induction of Polymorphic 4’-hydroxylation of S-mephenytoin by Rifampicin 60
Quinidine Reduces Clearance of（＋）-Propranolol More than（-）-Propranolol Through Marked Reduction in 4-Hydroxylation 64
Differences in Plasma Binding of Drugs Between Caucasians and Chinese Subjects 71
Increased Suppression of Exercise-Induced Increase in Renin by Propranolol in Chinese Subjects 78
Lack of Effect of Ageing on the Stereochemical Disposition of Propranolol 85
Differing Effect of Atropine on Heart Rate in Chinese and White Subjects 89
Ethnic Differences in Response to Morphine 94
Stereoselective Disposition of Carvedilol is Determined by CYP2D6 100
The Elimination of Diazepam in Chinese Subjects is Dependent on the Mephenytoin Oxidation Phenotype 107
In Vivo Inhibition of CYP2C19 But Not CYP2D6 by Fluvoxamine 112
Genetic Polymorphisms of Debrisoquine and S-mephenytoin Oxidation Metabolism in Chinese Populations：a Meta-analysis 116
Differences in the Incidence of the CYP2C19 Polymorphism Affecting the S-Mephenytoin Phenotype in Chinese Han and Bai Populations and Identification of a New Rare CYP2C19 Mutant Allele 121
Evidence for the Effect of Gender on Activity of（S）-Mephenytoin 4’-Hydroxylase （CYP2C19）in A Chinese Population 129
Meta-analysis of Phenotype and Genotype of NAT2 Deficiency in Chinese Populations 134
The Induction Effect of Rifampicin on Activity of Mephenytoin 4’-hydroxylase Related to M1 Mutation of CYP2C19 and Gene Dose 146
Evidence for Involvement of Polymorphic CYP2C19 and 2C9 in the N-demethylation of Sertraline in Human Liver Microsomes 149
Effect of the Gene Dosage of CYP2C 19 on Diazepam Metabolism in Chinese Subjects 157
Phenotypic Polymorphism and Gender-related Differences of CYP1A2 Activity in a Chinese Population 162
5-Hydroxylation of Omeprazole by Human Liver Microsomal Fractions from Chinese Populations Related to CYP2C19 Gene Dose and Individual Ethnicity 169
Ethnic Differences in Drug Metabolism 179
Effect of the CYP2C19 Oxidation Polymorphism on Fluoxetine Metabolism in Chinese Healthy Subjects 184
Pharmacokinetics of Sertraline in Relation to Genetic Polymorphism of CYP2C19 189
Plasma Caffeine Metabolite Ratio（17X/137X） in Vivo Associated with G-2964A and C734A Polymorphisms of Human CYP1A2 195
O-Dealkylation of Fluoxetine in Relation to CYP2C19 Gene Dose and Involvement of CYP3A4 in Human Liver Microsomes 202
Assessment of Cytochrome P450 Activity by a Five-drug Cocktail Approach 212
The Role of CYP2C19 in AmitriptylineN-demethylation in Chinese Subjects 219
Inducibility of CYP1A2 by Omeprazole in Vivo Related to the Genetic Polymorphism of CYP 1A2 225
Phenotypic Polymorphism of CYP2A6 Activity in a Chinese Population 229
Histamine N-methyltransferase Gene Polymorphisms in Chinese and Their Relationship with Enzyme Activity in Erythrocytes 235
Isozyme-specific Induction of Low-dose Aspirin on Cytochrome P450 in Healthy Subjects 246
Gly389Arg Polymorphism of β1-adrenergic Receptor is Associated with the Cardiovascular Response to Metoprolol 254
Pharmacokinetics of Citalopram in Relation to Genetic Polymorphism of CYP2C19 261
The Distribution and Gender Difference of CYP3A Activity in Chinese Subjects 268
St John’s Wort Induces Both Cytochrome P450 3A4-catalyzed Sulfoxidation and 2C19-dependent Hydroxylation of Omeprazole 274
Iiell8Val Genetic Polymorphism of CYP3A4 and Its Effects on Lipid-lowering Efficacy of Simvastatin in Chinese Hyperlipidemic Patients 281
Gender Specific Association of CYP2C9*3 with Hyperlipidaemia in Chinese 288
β1-Adrenergic Receptor Polymorphisms Influence the Response to Metoprolol Monotherapy in Patients with Essential Hypertension 291
Effect of SLCO1B1 Genetic Polymorphism on the Pharmacokinetics of Nateglinide 301
Frequency of Genetic Polymorphisms of COX 1，GP Ⅲ a and P 2Y1 in a Chinese Population and Association with Attenuated Response to Aspirin 307
SLCO1B1 521T→C Functional Genetic Polymorphism and Lipid-lowering Efficacy of Multiple-dose Pravastatin in Chinese Coronary Heart Disease Patients 316
The Effect of Herbal Medicine Baicalin on Pharmacokinetics of Rosuvastatin，Substrate of Organic Anion-transporting Polypeptide 1B1 322
Hepatic Nuclear Factor 1α Inhibitor Ursodeoxycholic Acid Influences Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 Substrate Rosuvastatin and Bilirubin 329
Effects of Ginkgo Biloba Extract on the Pharmacokinetics of Bupropion in Healthy Volunteers 334
Plant Polyphenol Curcumin Significantly Affects CYP1A2 and CYP2A6 Activity in Healthy，Male Chinese Volunteers 340
Pharmacogenetics of Drugs Withdrawn from the Market 349
三、周宏灏院士的主要学术著作 358
药理学 358
Textbook of Pharmacology 360
Case Files TM Pharmacology 363
Pharmacology 365
遗传药理学（第2版） 368
四、周宏灏院士重要学术报告、重要讲话 369
Ethnic Differences in Drug Response 369
Pharmacogenetic Research about Natural Medicine Effect of Natural Medicine on CYP450 370
Ethnic Differences in Drug Metabolism 372
Genetic Polymorphism of CYP2C19 in Chinese Populations 373
Pharmacogenetics and Pharmacogenomics in Asian Populations and Impact on Clinical Pharmacology 374
Racial Differences in Drug Response Reflect Differences in Distribution of Polymorphic Traits 375
Pharmacogenetic and Pharmacogenomic Research in China 376
Ethnicity，Genetics and Tailored Pharmacotherapy 377
个体化药物治疗的研究与开发 378
药物基因组学研究技术成果在药物临床评价中的应用 379
在临床试验中不能忽视亚洲人群种族差异的基因多态性 381
药物代谢酶基因多态性与个体化药物治疗 382
个体化医学的实施与展望 383
五、周宏灏院士学术年表 384
周宏灏院士论文目录 384
周宏灏院士专著目录 424
周宏灏院士科研与教学成果目录 425
周宏灏院士获国家发明专利目录 427
第三部分 治学之道 429
勤勉严谨做学问 情系祖国育桃李 431
遗传药理学研究的先行者 435
善于发现 勇于挑战——访临床药理学家周宏灏院士 439
中国遗传药理学开拓者周宏灏：立志如山 行道如水 445
周宏灏：中国个体化用药的“拓荒者” 449
让患者用药更精确 454
用药也需“量体裁衣”——访我国著名遗传药理学家周宏灏教授 456
第四部分 大师风范 461
一、感悟、经验与情怀 463
做人 做事 做学问 463
心系学子 桃李芬芳 以德服人 从严治学 465
医学教育不能硬套综合大学管理体制——中国工程院院士周宏灏谈我国医学教育现状与改革 467
春蚕到死丝方尽，人至期颐亦不休 470
我的情操 472
二、部分学生的代表性论文 475
Effect of Asymmetric Dimethylarginine on Osteoblastic Differentiation 475
Effect of SLCO1B1 Genetic Polymorphism on the Pharmacokinetics of Nateglinide 476
Evidence for Involvement of Calcitonin Gene-Related Peptide in Nitroglycerin Response and Association with Mitochondrial Aldehyde Dehydrogenase-2 （ALDH2） Glu504Lys Polymorphism 477
Molecular Population Genetics of Human CYP3A Locus：Signatures of Positive Selection and Implications for Evolutionary Environmental Medicine 478
Coupling HPLC to on-line，Post-column（bio） Chemical Assays for High-resolution Screening of Bioactive Compounds from Complex Mixtures 479
KCNJ 11 Lys23Glu and TCF7L2 rs290487（C/T） Polymorphisms affect Therapeutic Efficacy of Repaglinide in Chinese Patients with Type 2 Diabetes 480
Inhibition of the Organic Anion-transporting Polypeptide 1B1 by Quercetin：An in Vitro and in Vivo Assessment 481
Effect of eIF3a on Response of Lung Cancer Patients to Platinum-Based Chemotherapy by Regulating DNA Repair 482
The Pregnane X Receptor Agonist St John’s Wort Has No Effects on the Pharmacokinetics and Pharmacodynamics of Repaglinide 483
Effects of Lignans Extracted from Eucommia Ulmoides and Aldose Reductase Inhibitor Epalrestat on Hypertensive Vascular Remodeling 484
ABCC2 Polymorphisms and Haplotype are Associated with Drug Resistance in Chinese Epileptic Patients 485
Theragnostics Meets Traditional Chinese Medicine：Rational Prediction of Drug-herb Interactions 486
Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer（NSCLC） Patients 487
Protective Effects of Eucommia Lignans Against Hypertensive Renal Injury by Inhibiting Expression of Aldose Reductase 488
Translational Regulation of RPA2 Via Internal Ribosomal Entry Site and by eIF3a 489
Effect of NR3C2 Genetic Polymorphisms on the Blood Pressure Response to Enalapril Treatment 490
The KCNH2 Genetic Polymorphism（1956，C＞T） Is a Novel Biomarker That Is Associated with CCB and α，β-ADR Blocker Response in EH Patients in China 491
Polymorphism of ORM1 Is Associated with the Pharmacokinetics of Telmisartan 492
Current Pharmacogenomic Studies on hERG Potassium Channels 493
Deficiency of Multidrug and Toxin Extrusion 1 Enhances Renal Accumulation of Paraquat and Deteriorates Kidney Injury in Mice 494
Effects of the Peroxisome Proliferator Activated Receptor-γ Coactivator-lα（PGC-1α） Thr394Thr and Gly482Ser Polymorphisms on Rosiglitazone Response in Chinese Patients with Type 2 Diabetes Mellitus 495
Characterization and Analyses of Multidrug Resistance-associated Protein 1 （MRP1/ABCC 1）Polymorphisms in Chinese Population 496
第五部分 社会影响 497
我学者首次发现不同种族对药物的差异性 499
Effectiveness of Drugs May be Influenced by Racial and Ethnic History 500
深入了解中国人的心脏 502
种族与药物的治疗效应 503
β-受体阻滞药效应呈现种族差异 505
药物效应的种族差异 507
我国医学科技占世界之首成果巡礼 509
Biomedicine 510
DNA Chips Bring Personalized Medicine to China 512
开拓国际临床药理新领域——记中国工程院院士周宏灏 515
世界首张个体化用药基因芯片初步研制成功 521
个体化用药成为焦点 522
用多少药，问问你的遗传基因 523
基因芯片：有助于药物治疗个体化 524
用药也可“量体裁衣” 525
周宏灏教授当选世界药理学联合会药物代谢学会理事 526
省儿童医院聘请周宏灏为终身首席科学家 527
引领人类个体化用药新时代的人——记我国著名临床与遗传药理学家周宏灏教授 528
研发一体化做强湖南医药产业——访中国遗传药理学专家、中南大学临床药理研究所所长、中国工程院院士周宏灏教授 538
种族差异、遗传及个体化药物治疗 542
第六部分 人生风采 543
成长历程 545
教书育人 547
学术交流 550
珍贵合影 553
人文情怀 555